S-5751

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C25H31NO4S
Molecular Weight	441.583
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1(C)[C@@H]2C[C@H]1[C@H](NC(=O)C3=CSC4=C3C=C(O)C=C4)[C@@H](C\C=C/CCCC(O)=O)C2

InChI

InChIKey=ZXBHFWFKSIYJEK-MFJOXFORSA-N

InChI=1S/C25H31NO4S/c1-25(2)16-11-15(7-5-3-4-6-8-22(28)29)23(20(25)12-16)26-24(30)19-14-31-21-10-9-17(27)13-18(19)21/h3,5,9-10,13-16,20,23,27H,4,6-8,11-12H2,1-2H3,(H,26,30)(H,28,29)/b5-3-/t15-,16-,20-,23+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C25H31NO4S
Molecular Weight	441.583
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	1
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11454901 | http://www.shionogi.co.jp/en/company/news/2006/pmrltj0000001d4d-att/e_061027.pdf
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/21596028

S-5751, an orally active prostanoid DP receptor antagonist, had potent anti-inflammatory effects in guinea pig and sheep asthma models. S-5751 had been in phase II clinical trials by Shionogi for the treatment of bronchial asthma. However, this study was discontinued in 2006.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Prostanoid DP receptor 16 Target ID: CHEMBL4427 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12773048 \| https://www.ncbi.nlm.nih.gov/pubmed/11454901	Antagonist 2849		0.9 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Asthma 244 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21596028 http://adisinsight.springer.com/drugs/800012090	Primary		Phase I 438	Unknown Approved Use Unknown

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252	inhibitor 2438	inhibitor 2507

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	P-gp 2052

Drug as perpetrator

Target	Modality	Activity
CYP2D6 2546	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1645840#sid=363680345	no
CYP2C9 2497	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1645842#sid=363680345	yes [IC50 1.345 uM]
CYP3A4 2633	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1645841#sid=363680345	yes [IC50 9.5221 uM]

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 2052	substrate 4014 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1346987#sid=363680345	no

Sourcing

Vendor/Aggregator	ID	URL
Axon MedChem	1605	https://www.axonmedchem.com/product/1605
Cayman Chemical	10004030	http://www.caymanchem.com/app/template/Product.vm/catalog/10004030
eMolecules	44848343	https://orderbb.emolecules.com/search/#?query=44848343
MolPort	MolPort-042-665-721	https://www.molport.com/shop/molecule-link/MolPort-042-665-721
Toronto Research Chemicals	S080600	https://www.trc-canada.com/product-detail/?CatNum=S080600

PubMed

Title	Date	PubMed

Patents

Sample Use Guides

In Vivo Use Guide

Rats: S-5751 and pinagladin were orally administered to BN rats three times a day at a maximum dose of 100 mg/kg

Route of Administration: Oral

In Vitro Use Guide

S-5751 inhibited PGD(2)-induced cAMP production in platelet-rich plasma with an IC(50) value of 0.12 uM..

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:01:42 GMT 2025` Edited by `admin` on `Mon Mar 31 18:01:42 GMT 2025`
Record UNII	GA0E7U1R52
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

S-5751

Common Name

English

5-HEPTENOIC ACID, 7-((1R,2R,3S,5S)-2-(((5-HYDROXYBENZO(B)THIEN-3-YL)CARBONYL)AMINO)-6,6-DIMETHYLBICYCLO(3.1.1)HEPT-3-YL)-, (5Z)-

Preferred Name

English

(5Z)-7-((1R,2R,3S,5S)-2-(((5-HYDROXY-1-BENZOTHIEN-3-YL)CARBONYL)AMINO)-6,6-DIMETHYLBICYCLO(3.1.1)HEPT-3-YL)HEPT-5-ENOIC ACID

Systematic Name

English

Code System Code Type Description

FDA UNII

GA0E7U1R52

Created by admin on Mon Mar 31 18:01:42 GMT 2025 , Edited by admin on Mon Mar 31 18:01:42 GMT 2025

PRIMARY

CAS

209268-36-0

Created by admin on Mon Mar 31 18:01:42 GMT 2025 , Edited by admin on Mon Mar 31 18:01:42 GMT 2025

PRIMARY

PUBCHEM

9867949

Created by admin on Mon Mar 31 18:01:42 GMT 2025 , Edited by admin on Mon Mar 31 18:01:42 GMT 2025

PRIMARY

Related Record Type Details


					GA0E7U1R52

S-5751

ACTIVE MOIETY

Details

SMILES

InChI

DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/11454901 | http://www.shionogi.co.jp/en/company/news/2006/pmrltj0000001d4d-att/e_061027.pdfCurator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/21596028

Originator

Approval Year

Targets

Conditions

Approved Use

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Sourcing

PubMed

Patents

Sample Use Guides

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11454901 | http://www.shionogi.co.jp/en/company/news/2006/pmrltj0000001d4d-att/e_061027.pdf
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/21596028

Drug as perpetrator